Abbott Laboratories revenue and financials
$98.16Change from previous close: −1.94%Absolute change: −$1.94
In the fiscal year ended December 2025, Abbott Laboratories reported revenue of $44.33B (+5.67% year over year). Net income was $6.52B, a net margin of 14.7%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +5.67%
- 2025 vs 2024
- Net income growth
- −51.32%
- 2025 vs 2024
- Net margin
- 14.7%
- 2024: 31.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 109,215 | 110,429 | 86,713 | 84,181 | 83,999 | 81,448 | 81,414 | 74,356 | 73,017 | 72,467 | 73,214 | 72,090 |
| Current assets | 24,517 | 25,508 | 25,996 | 24,839 | 24,468 | 23,153 | 23,656 | 23,802 | 23,119 | 22,376 | 22,670 | 22,664 |
| Cash and equivalents | 5,104 | 6,803 | 8,522 | 7,511 | 6,951 | 6,532 | 7,616 | 7,558 | 6,987 | 6,284 | 6,896 | 6,709 |
| Short-term investments | 499 | 492 | 417 | 222 | 331 | 312 | 351 | 230 | 232 | 367 | 383 | 338 |
| Receivables | 8,599 | 8,210 | 7,929 | 8,138 | 7,972 | 7,327 | 6,925 | 7,051 | 6,854 | 6,605 | 6,565 | 6,499 |
| Inventory | 7,315 | 6,989 | 6,488 | 6,708 | 6,954 | 6,639 | 6,194 | 6,813 | 6,814 | 6,827 | 6,570 | 6,650 |
| Net property, plant and equipment | 12,812 | 12,377 | 12,942 | 11,504 | 11,395 | 10,932 | 11,733 | 10,621 | 10,233 | 10,107 | 11,276 | 9,552 |
| Goodwill | 35,244 | 35,221 | 24,035 | 23,971 | 23,952 | 23,359 | 23,108 | 23,658 | 23,308 | 23,383 | 23,679 | 23,277 |
| Other intangible assets | 17,211 | 17,875 | 5,526 | 5,598 | 5,920 | 6,261 | 6,647 | 7,352 | 7,827 | 8,296 | 8,815 | 9,282 |
| Long-term investments | 783 | 781 | 595 | 626 | 643 | 606 | 573 | 589 | 566 | 501 | 485 | 497 |
| Current liabilities | 17,814 | 18,377 | 16,496 | 14,582 | 13,439 | 13,004 | 14,157 | 14,902 | 13,760 | 14,021 | 13,841 | 13,042 |
| Accounts payable | 4,794 | 4,679 | 4,240 | 4,123 | 4,306 | 4,214 | 4,195 | 4,034 | 4,125 | 4,178 | 4,295 | 3,961 |
| Long-term debt | 29,703 | 29,705 | 9,896 | 11,630 | 12,963 | 12,784 | 12,676 | 12,879 | 13,213 | 12,664 | 13,694 | 14,635 |
| Total debt | 32,720 | 34,136 | 14,136 | 12,975 | 13,470 | 13,290 | 15,326 | 15,046 | 14,845 | 14,705 | — | — |
| Total liabilities | 57,453 | 57,728 | 33,942 | 32,917 | 33,170 | 32,384 | 33,513 | 34,328 | 33,457 | 33,424 | 34,387 | 34,396 |
| Total equity (incl. minority) | 51,762 | 52,701 | 52,771 | 51,264 | 50,829 | 49,064 | 47,901 | 40,028 | 39,560 | 39,043 | 38,827 | 37,694 |
| Retained earnings | 49,794 | 49,956 | 49,781 | 49,103 | 48,467 | 47,715 | 47,261 | 39,056 | 38,354 | 38,011 | 37,554 | 36,920 |
| Minority interest | 652 | 640 | 641 | 310 | 264 | 253 | 237 | 232 | 242 | 233 | 224 | 213 |
